newsfilter
← Latest News
ACCESS Newswire·

Precigen Reports 'Robust Uptake' of New Drug for Rare Respiratory Disease; First Quarter Revenue Expected to Top $18 Million

Plans Underway to Expand Use to Pediatrics, Patient Redosing and European ApprovalMeg Flippin, Benzinga Staff WriterGERMANTOWN, MD / ACCESS Newswire / April 7, 2026 / Precigen Inc. , a commercial-stage